Research Perspectives in Psoriasis (AAD 2021)

To participate in this activity, please:

Plaque psoriasis is responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances continue to be made, including a better understanding of the long-term safety and efficacy of approved medications, as well as the introduction of new classes of medications. Join Steven Feldman, MD, PhD, and Abby Van Voorhees, MD, as they report on research results of these advances presented at the 2021 American Academy of Dermatology Virtual Meeting Experience. The faculty, and principal investigators of the research, also share their thoughts about the impact of the research findings on clinical practice.

Course Credit:

1.25 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2021-06-11
Closes: 2022-06-11

Target Audience:

This activity is intended for dermatologists, pediatric dermatologists, and other clinicians who manage patients with moderate-to-severe plaque psoriasis.

This educational activity is supported by an educational grant from AbbVie, Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, and Novartis Pharmaceuticals Corp.
  • Steven R. Feldman, MD, PhD

    Professor of Dermatology, Pathology, and Social Sciences & Health Policy
    Wake Forest University Health Sciences
    Winston-Salem, North Carolina

  • Abby S. Van Vorhees, MD

    Professor and Chair, Department of Dermatology
    Eastern Virginia Medical School
    Norfolk, Virginia

Learning Objectives

  • Summarize the latest research developments in the treatment of plaque psoriasis
  • Describe how new data and recommendations can impact clinical practices to improve care
  • Incorporate evidence-based research into clinical practice

Faculty Disclosures

Steven R. Feldman, MD, PhD

Chief Technology Officer: Causa Technologies

Consultant: AbbVie, Advance Medical, Almirall, Alvotech, Amgen, Arcutis, Arena, BMS, Caremark, Celgene, Dermavant, Galderma Laboratories, LP, Gerson, Lehrman Group, Guidepoint Global, Helsinn, Janssen, Kikaku, Leo Pharma Inc, Lilly, Merck & Co, Inc, Mylan, Novartis Pharmaceuticals Corporation, Ortho Dermatology, Pfizer Inc, Regeneron, Sanofi, Sienna, Sun Pharma, Suncare Research, XenoPort

Founder: Causa Technologies

Grant Support: AbbVie, Amgen, Celgene, Galderma Laboratories, LP, Janssen, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron, Sanofi

Royalties: Informa, UpToDate, Xlibris

Speakers Bureau: AbbVie, Amgen, Celgene, Janssen, Leo Pharma Inc, Lilly, Novartis      Pharmaceuticals Corporation, Ortho Dermatology, Pfizer Inc, Regeneron, Sanofi, Sun Pharma

Stockholder: Causa Technologies, Medical Quality Enhancement Corporation


Abby S. Van Vorhees, MD

Advisory Board: BMS, Boehringer Ingelheim, Celgene, UCB

Consultant: Amgen

Investigator: AbbVie, Celgene, Lilly

Research Support: Boehringer Ingelheim


Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.